1412P SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors
| Autor: | Curioni-Fontecedro, A., Holer, L., Frueh, M., Weindler, S., König, D., Addeo, A., Britschgi, C., Rigutto, A., Waibel, C., Bettini, A., Cerciello, F.W.F., Hiltbrunner, S., Nguyen, D.L., Zellweger, C., Musilova, J., von Moos, R.A.F., Joerger, M. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S807-S808 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|